ACM
IMRX icon

Alethea Capital Management’s Immuneering IMRX Stock Holding History

Alethea Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Hold
22,935
– – 0.06% 12
2025
Q4 		$151K Hold
22,935
– – 0.07% 11
2025
Q3 		$161K Hold
22,935
– – 0.1% 31
2025
Q2 		$77.3K Buy
+22,935
New +$39.3K 0.06% 29

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alethea Capital Management's IMRX Position: Q1 2026 in Review

Alethea Capital Management held its Immuneering (IMRX) position steady in Q1 2026 at 22,935 shares worth $121K. The position accounts for 0.06% of the portfolio, ranked #12.

Alethea Capital Management first reported a position in IMRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $161K in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Alethea Capital Management held 22,935 shares of Immuneering worth $121K as of Q1 2026.
  • Alethea Capital Management left its Immuneering share count unchanged in Q1 2026.
  • Immuneering made up 0.06% of Alethea Capital Management's portfolio in Q1 2026, its #12 holding.
  • Alethea Capital Management first reported a position in Immuneering in Q2 2025 and has held it in 4 quarters since.
  • Alethea Capital Management's Immuneering position peaked at $161K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Alethea Capital Management's 13F filing for Q1 2026, filed 13 May 2026.